SCHEMBL2486259

SCHEMBL2486259

COc1cccc(O)c1CC=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
TP53 P04637 2/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPT P10636 2/20 0.52
MAPK1 P28482 2/20 0.52
HPGD P15428 2/20 0.52
HSD17B10 Q99714 2/20 0.52
LMNA P02545 1/20 0.52
CYP3A4 P08684 1/20 0.52
ALOX15 P16050 1/20 0.52
ALOX12 P18054 1/20 0.52
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
TSHR P16473 1/20 0.48
TLR2 O60603 1/20 0.47
ERN1 O75460 1/20 0.47
TLR1 Q15399 1/20 0.47
TLR6 Q9Y2C9 1/20 0.47
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3128179 0.87 TLR2 (0.46) ALDH1A1TP53KDM4EMAPTMAPK1
SCHEMBL16098438 0.83 BACE1 (0.42) ALDH1A1TP53KDM4EMAPTMAPK1
SCHEMBL2479613 0.82 ALDH1A1 (0.52) ALDH1A1TP53KDM4EMAPTMAPK1
SCHEMBL8702045 0.81 CYP3A4 (0.50) ALDH1A1TP53KDM4EMAPTMAPK1
SCHEMBL2727597 0.80 ERN1 (0.43) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL14135236 0.80 TLR2 (0.41) ALDH1A1KDM4EHPGDHSD17B10CYP3A4
SCHEMBL8717485 0.79 KDM4E (0.48) ALDH1A1TP53KDM4EMAPTMAPK1
SCHEMBL8717482 0.79 KDM4E (0.48) ALDH1A1TP53KDM4EMAPTMAPK1
SCHEMBL17377670 0.79 ERN1 (0.45) ALDH1A1TP53KDM4EMAPTMAPK1
SCHEMBL9900164 0.79 ALDH1A1 (0.48) ALDH1A1KDM4EMAPTHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3325468-A1 CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS Eli Lilly and Company (US) 2018-05-30 EP disclosed
WO-2017015124-A1 CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS ELI LILLY AND COMPANY (US) 2017-01-26 WO disclosed
EP-2398809-A1 NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE Merck Canada Inc. (CA) 2011-12-28 EP disclosed
EP-2379532-A1 COMPOUNDS USEFUL FOR INHIBITING CHK1 Eli Lilly and Company (US) 2011-10-26 EP disclosed
WO-2010094120-A1 NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-08-26 WO disclosed
WO-2010077758-A1 COMPOUNDS USEFUL FOR INHIBITING CHK1 ELI LILLY AND COMPANY (US) 2010-07-08 WO disclosed
EP-1711490-A4 NOVEL P-GLYCOPROTEIN INHIBITOR, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HANMI PHARM IND CO LTD (KR) 2007-04-04 EP disclosed
EP-1711490-A1 NOVEL P-GLYCOPROTEIN INHIBITOR, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Hanmi Pharm. Co., Ltd. (KR) 2006-10-18 EP disclosed
EP-1651631-A1 BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE GENELABS TECHNOLOGIES, INC. (US) 2006-05-03 EP disclosed
WO-2005033101-A1 NOVEL P-GLYCOPROTEIN INHIBITOR, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HANMI PHARM. CO., LTD. (KR) 2005-04-14 WO disclosed
WO-2005012288-A1 BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE GENELABS TECHNOLOGIES, INC (US) 2005-02-10 WO disclosed